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Abstract
Background: Cross-sectional assessment of HIV incidence relies on laboratory methods to discriminate between recent and
non-recent HIV infection. Because HIV diversifies over time in infected individuals, HIV diversity may serve as a biomarker for
assessing HIV incidence. We used a high resolution melting (HRM) diversity assay to compare HIV diversity in adults with
different stages of HIV infection. This assay provides a single numeric HRM score that reflects the level of genetic diversity of
HIV in a sample from an infected individual.
Methods: HIV diversity was measured in 203 adults: 20 with acute HIV infection (RNA positive, antibody negative), 116 with
recent HIV infection (tested a median of 189 days after a previous negative HIV test, range 14–540 days), and 67 with non-
recent HIV infection (HIV infected.2 years). HRM scores were generated for two regions in gag, one region in pol, and three
regions in env.
Results: Median HRM scores were higher in non-recent infection than in recent infection for all six regions tested. In
multivariate models, higher HRM scores in three of the six regions were independently associated with non-recent HIV
infection.
Conclusions: The HRM diversity assay provides a simple, scalable method for measuring HIV diversity. HRM scores, which
reflect the genetic diversity in a viral population, may be useful biomarkers for evaluation of HIV incidence, particularly if
multiple regions of the HIV genome are examined.
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Introduction
Accurate methods for measuring HIV incidence using cross-
sectional samples are important for monitoring the HIV epidemic
and assessing the efficacy of interventions for HIV prevention [1].
Most cross-sectional HIV incidence studies have been performed
using serologic assays, such as the BED capture immunoassay [2].
Serologic HIV incidence assays are based on the premise that the
antibody response to HIV matures over time. Unfortunately, some
individuals never attain a mature anti-HIV antibody response, and
individuals with non-recent HIV infection may be misclassified as
recently infected if the antibody response to HIV is blunted by
viral suppression or advanced HIV disease [3,4].
Because HIV generally diversifies over time in infected
individuals, HIV diversity may serve as a biomarker for assessing
HIV incidence [5]. Most studies of HIV diversity have used
sequence-based methods to analyze individual HIV variants in
infected individuals [6,7,8]. Those studies demonstrate that HIV
infection is usually initiated by one or a small number of founder
virions [9]. Over time, rapid viral replication, frequent mutation,
and frequent recombination events generate large numbers of
distinct viral variants [9,10]. Immune responses to infection,
antiretroviral therapy (ART), and other selective pressures drive
the diversification and evolution of the viral population [9,11].
Previous reports suggest that env sequences are usually homoge-
neous early in infection [12,13,14], with higher levels of diversity
accompanying higher multiplicity of infection [12,13]. After HIV
infection is established, env diversity usually increases over time and
stabilizes or declines in advanced stages of HIV disease [7,14,15].
Genetic diversification in env and gag may be concordant or
discordant over the course of infection [16,17]. Differences in viral
diversification in these two regions may reflect different selective
pressures targeting env and gag proteins [16,18].
While sequencing-based studies of HIV diversity have been
informative, the cost and effort needed to sequence viral variants
(e.g., by cloning, single genome sequencing, or parallel sequencing)
make those methods impractical for analysis of HIV incidence in
larger cohorts or surveillance studies, which may require analysis
of hundreds or thousands of samples. Recent reports have found
that the frequency of ambiguous nucleotide calls in population
sequencing data may reflect HIV diversity [19,20]. This approach
may be useful for assessing HIV diversity using existing sequence
databases generated for surveillance of HIV drug resistance.
However, patterns of HIV diversity can vary from one genomic
region to another, and genetic bottlenecking may occur in some
regions during the course of HIV infection. Therefore, discrim-
ination between recent and non-recent HIV infection may require
analysis of diversity in more than one region of the HIV genome.
For such an approach to be practical for HIV incidence
applications, simpler methods are needed for HIV diversity
analysis. Heteroduplex mobility assays can be used to analyze
HIV diversity without sequencing [14]. In those assays, genetic
diversity is quantified by analyzing the mobility pattern of
amplified DNA in a gel. Unfortunately, the requirement for gel
electrophoresis increases the time and effort needed for analysis
and makes heteroduplex mobility assays difficult to scale up for
high-throughput analysis.
We recently developed a rapid assay for HIV diversity based on
high resolution melting (HRM) technology [21]. Assays based on
HRM of DNA duplexes have been used to detect mutations
associated with cancer and genetic diseases; HRM technology is
also being developed for analysis of specific mutations in bacterial,
viral, and parasitic pathogens [22]. We adapted HRM technology
to quantify genetic diversity in HIV [21,23]. The HRM diversity
assay is performed in a 96-well plate format, and each melting
procedure takes only a few minutes. The HRM diversity assay
provides a single numeric HRM score that reflects the level of HIV
diversity in a specific region of the HIV genome, simplifying data
analysis. Calculation of the HRM score is straightforward and can
be automated using the electronic output of the melting
instrument. The HRM diversity assay is highly reproducible,
and HRM scores are significantly associated with sequence-based
diversity measures such as genetic diversity, genetic complexity,
and Shannon entropy [21,23]. In this report, the HRM diversity
assay was used to compare, gag, pol, and env diversity in samples
from 203 adults with different stages of HIV infection. These data
suggest that the HRM diversity assay may be useful for analysis of
HIV incidence.
Methods
Human subjects (Ethics Statement)
The EXPLORE, HIVNET 001, Johns Hopkins HIV Clinical
Cohort (JHHCC), and Johns Hopkins Hospital Emergency
Department (JHH ED) studies were conducted according to the
ethical standards set forth by the institutional review boards of the
participating institutions and the Helsinki Declaration of the
World Medical Association; participants provided written, in-
formed consent [24,25,26,27]. The work described in this report
involved analysis of stored samples and data from those studies. No
participants were recruited or followed in the course of this work.
The work described in this report was approved by the Internal
Review Board at the Johns Hopkins University School of
Medicine.
Samples used for analysis
Samples were collected from adults in the United States. Acute
samples (HIV RNA positive, HIV antibody negative [28], Feibig
stage I or II [29], n = 20) and recent samples (collected near the
time of HIV seroconversion, likely Feibig stage VI [29], n = 102)
were obtained from men who have sex with men (MSM) in the
EXPLORE study [24] (1999-2001, median age: 31 years, range
19-56 years, 66% Caucasian). Additional recent samples (collected
near the time of HIV seroconversion, likely Feibig stage VI [29],
n = 14) were obtained from the HIVNET 001 study [25] (1995–
1997) from ten heterosexual intravenous drug users (IDUs, six
women and four men) and four heterosexual women who were not
IDUs. The median time between collection of recent samples and
the last negative HIV test was 189 days (range 14–540) for the
EXPLORE study and 165 days (range: 49–216) for the HIVNET
001 study.
Samples from adults with non-recent HIV infection (infected
.2 years) were obtained from two sources: (1) The Johns Hopkins
HIV Clinical Cohort (JHHCC) study of HIV-infected patients in
Baltimore (2002–2008, n = 56) [26], and (2) Johns Hopkins
Hospital Emergency Department (JHH ED) HIV serosurvey
(2001 and 2003, n= 11) [27]. Characteristics of the non-recent
group (n= 67, JHHCC and JHH ED) were: 72% men, 36%
Caucasian (53 had data for gender or race), median age: 36 years
(range: 21–53 years; 60 had data for age), median log10 HIV viral
load: 5.2 log10 copies/ml (range: 3.6–5.9 log10 copies/ml, 55 had
data for viral load), and median CD4 cell count: 43 cells/mm3
(range: 1–388 cells/mm3, 57 had data for CD4 cell count).
Preparation of DNA for HRM analysis
HIV RNA was extracted from plasma or serum using the
ViroSeq HIV Genotyping System (Celera, Alameda, CA). HIV
DNA used to analyze gag and pol was prepared using the ViroSeq
HRM Analysis of HIV Diversity
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system. HIV DNA used to analyze env was prepared using the
Qiagen OneStep RT-PCR Kit (QIAGEN Inc., Valencia, CA;
forward primer: JH35F (59-TGARGGACAATTGGAGAA-
RTGA-39); reverse primer JH38R (59-GGTGARTATCCCTK-
CCTAAC-39) [30,31]). PCR products were purified using
ExoSAP-IT (United States Biochemical Corporation, Cleveland,
OH) and were diluted to approximately 0.5 ng/ml for HRM
analysis.
Preparation of plasmid controls
DNA (gag-pol and env amplicons) amplified from five recent
samples (EXPLORE study) was cloned into the vector, pCRH2.1-
TOPO (TOPO TA CloningH Kit, Invitrogen, Carlsbad, CA).
Plasmids were diluted to approximately 5 ng/ml for HRM
analysis.
HRM diversity analysis
The HRM diversity assay was performed as previously
described [21]. Six regions of the HIV genome were amplified
in the presence of LCGreenH Plus dye (Idaho Technology Inc.,
Salt Lake City, UT, Table 1, Figure 1). The amplicons were
melted using the LightScanner Instrument (Model HR 96, Idaho
Technology Inc., Salt Lake City, UT), and release of the dye was
quantified as a function of temperature (melting range for gag and
pol amplicons: 68–98uC with a 65uC hold; melting range for env
amplicons: 60–98uC with a 57uC hold). Melting curves were used
to determine HRM scores, as described previously [21], using a
15uC window size. Samples were analyzed in duplicate and the
results were averaged; if the difference in the duplicate HRM
scores was .0.5, the data were rejected, and the samples were
reanalyzed.
Statistical methods
The Wilcoxon rank sum test was used to compare HRM scores
from different sample sets (e.g., non-recent vs. recent) for each
region. Outlier values were defined as greater than the third
quartile + (1.5 x interquartile range [IQR]) or less than the first
quartile – (1.5 x IQR). Extreme values were defined as values
greater than the third quartile + (3 x IQR) or less than the first
quartile – (3 x IQR). Logistic regression was used to assess HRM
scores for recent and non-recent infection for all six regions both
separately and jointly. The Wilcoxon rank sum test was used to
compare HRM scores for adults in different subgroups (e.g., with
and without ART). Analyses were performed using SAS software
version 9.2 (Cary, North Carolina).
Results
The HRM diversity assay was used to analyze six regions in the
HIV genome: two regions in HIV gag (GAG1 and GAG2), one
region in HIV pol (POL), and three regions in HIV env (ENV1,
ENV2, and ENV3; Figure 1, Table 1). HRM scores for each
region were all less than 5.2 for control plasmids (Figure 2).
Region-specific differences in HRM scores for the plasmids most
likely reflect differences in the length and melting domain
characteristics of the amplicons [32].
The HRM diversity assay was used to analyze samples from 189
adults with different stages of HIV infection (20 with acute HIV
infection [EXPLORE study], 102 with recent HIV infection
[EXPLORE study], and 67 with non-recent HIV infection
[JHHCC and JHU ED], see Methods). ART use and low CD4
cell count have been associated with misclassification of individuals
with non-recent infection as recently infected using serologic HIV
incidence assays [3,4]. To test whether this type of misclassification
would also complicate use of the HRM diversity assay for HIV
incidence testing, the non-recent sample set was selected to include
a high proportion of ‘‘challenge’’ samples; 30 (44.8%) of the 67
non-recent samples were from adults on ART and 32 (48%) of the
67 non-recent samples were from adults with advanced HIV
disease (CD4 cell counts ,50 cells/mm3).
The HRM scores obtained for adults with acute HIV infection
were all low (,6.3). The median HRM scores for those samples
were significantly higher than the median scores for control
plasmids for all of the regions except GAG2 (Figure 2). The
highest median HRM score for acute samples was obtained for the
ENV2 region which includes the immunodominant region (IDR)
cluster I of HIV gp41 (Figure 1) [33]. The median HRM scores
obtained for adults with recent HIV infection (seroconversion
samples) were significantly higher than the median scores obtained
Table 1. Regions of the HIV genome analyzed using the high resolution melting (HRM) diversity assay.
Region
analyzeda
Corresponding
region in HXB2a
Sequences of primers used to produce
amplicons for HRM diversity analysisb Amplicon size (bp)
GAG1 1998 – 2097 Forward: 59- AAATTGCAGGGCCCCTAGGAA 100
Reverse: 59- TTTCCCTAAAAAATTAGCCTGTCT
GAG2 2068 – 2278 Forward: 59- ACTGAGAGACAGGCTAATTTTTTAG 211
Reverse: 59- GGTCGTTGCCAAAGAGTGATTTG
POL 2373 – 2597 Forward: 59- AAATGGAAACCAAAAATGATAG 225
Reverse: 59- CATTCCTGGCTTTAATTTTACTG
ENV1 7798 – 8036 Forward: 59- CAGCAGGWAGCACKATGGG 239
Reverse: 59- GCARATGWGYTTTCCAGAGCADCC
ENV2 7950 – 8119 Forward: 59- CTYCAGRCAAGARTCYTGGC 170
Reverse: 59- TCCCAYTSCAKCCARGTC
ENV3 8016 – 8299 Forward: 59- TGCTCTGGAAARCWCATYTGC 284
Reverse: 59- AARCCTCCTACTATCATTATRA
aSee Figure 1.
bMixed nucleotides were present at some positions (W: A/T; K: G/T; R: A/G; Y: C/T; D: A/G/T; S: G/C).
doi:10.1371/journal.pone.0027211.t001
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for adults with acute infection for all of the regions except ENV2
(Figure 2).
In all six regions analyzed, the median HRM scores for adults
with non-recent infection (infected .2 years) were significantly
higher than the median scores for adults with recent HIV infection
(P = 0.005 for ENV2, P,0.0001 for the other regions, Figure 2).
Higher HRM scores in each region were associated with non-
recent infection in logistic regression models (compared to recent
HIV infection, P,0.02 for ENV2, P,0.0001 for all other regions;
Table 2). In a multivariate logistic regression model, HRM scores
in three regions were independently associated with non-recent
infection (GAG2: P,0.04, ENV1: P,0.004, and ENV2:
P,0.0004; Table 2). Correlation plots for HRM scores in these
three regions in adults with acute, recent, and non-recent infection
are shown in Figure 3. In general, acute and recent infection
samples had low HRM scores in all three regions, while non-
recent infection samples had higher HRM scores (e.g., .6) in at
least one of the three regions (Figures 3 and 4).
HRM scores for adults with non-recent infection who had CD4
cell counts above vs. below 50 cells/mm3 were not significantly
different for five of the six regions analyzed. For the POL region,
the median HRM score was 5.6 for adults with CD4 cell counts
,50 cells/mm3 vs. 5.1 for adults with CD4 cell counts .50 cells/
mm3 (P= 0.006, Wilcoxon test). In Figure 2, we show the
distribution of the HRM scores obtained for each group of
participants. A total of 402 HRM scores were included in the
analysis of participants with non-recent infection (67 samples, 6
regions each). Six (1.5%) of the 402 HRM scores were outlier or
extreme values (see Methods); all six of those scores were from
adults who had CD4 cell counts ,50 cells/mm3. As shown in
Figure 2, all of those outlier / extreme values are high values,
indicating the presence of viral populations that had high levels of
diversity in the regions analyzed. Note that all of the HRM scores
(including the outlier / extreme HRM scores) were included in the
analysis. The unusually high levels of viral diversity in some adults
with very low CD4 cell counts enhances our ability to discriminate
between adults with recent HIV infection and adults with non-
recent HIV infection, including those with advanced HIV disease.
There was no significant association between antiretroviral drug
use and HRM score for any of the six regions (not shown).
In the analysis described above, adults with recent infection
were all MSM; three (3%) of those men reported using intravenous
drugs in the six months before HIV seroconversion. In contrast,
the non-recent group included both men and women, most of
whom likely acquired HIV infection through intravenous drug use.
Some studies indicate that the number of HIV variants present
very early in HIV infection varies among different risk groups
[12,13,34,35]. Therefore, differences in HRM scores between
these two groups (recent and non-recent) may have reflected their
different demographic characteristics and risk factors for HIV
Figure 1. Regions of the HIV genome analyzed using the HRM diversity assay. The relevant regions of the HIV genome are shown (adapted
from [39]). Numbers at the ends of each genomic segment correspond to coordinates in HXB2 (Genbank accession number: K03455). The amplicons
used for HRM diversity analysis (regions analyzed) are indicated by shaded boxes. (A) Gag and pol amplicons: The GAG1 amplicon includes a portion
of the coding regions for gag p7 and gag p1. The GAG2 amplicon includes the coding regions for gag p1 and gag p6 and extends into the coding
region for HIV protease (PR); this amplicon also corresponds to the transframe (TF) protein. The POL amplicon spans the junction between the coding
regions of HIV protease and HIV reverse transcriptase (RT). (B) Env amplicons: The ENV1 amplicon includes the coding region for heptad repeat 1
(HR1) of gp41, as well as portions of the coding regions to either side of HR1. The ENV3 amplicon includes the coding region for heptad repeat 2
(HR2), as well as portions of the coding regions to either side of HR2. The ENV2 amplicon includes the coding region for immunodominant region
(IDR) cluster I of gp41, as well as portions of the coding regions for HR1 and HR2 [33].
doi:10.1371/journal.pone.0027211.g001
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acquisition, rather than the duration of HIV infection. To address
this possibility, we tested additional samples from women and
heterosexual men, most of whom were IDUs (HIVNET 001
cohort, see Methods). In the GAG1, GAG2, POL, and ENV3
regions, HRM scores for men in the EXPLORE cohort and the
adults in the HIVNET 001 cohort were not significantly different;
HRM scores for two regions (ENV1 and ENV2) were slightly
lower for adults in the HIVNET 001 cohort (Table 3). This
indicates that the lower HRM scores observed in the recent group
from EXPLORE compared to the non-recent group (from the
JHHCC and JHU ED serosurvey) most likely reflect differences in
HIV diversity in recent vs. non-recent HIV infection rather than
differences in the demographic characteristics and risk factors of
the specific cohorts tested.
Discussion
We used a novel HRM diversity assay to compare HIV diversity
in adults with different stages of HIV disease. Adults with acute
HIV infection had uniformly low HRM scores (low levels of HIV
diversity). However, the median HRM scores for those individuals
were significantly higher than those obtained for plasmid controls
Figure 2. HRM scores for plasmid controls and samples from adults with different stages of HIV disease. The box and whisker plots
show the distribution of HRM scores for six regions in the HIV genome in control plasmids (n = 5; Subtype B) and in adults with acute (n = 20), recent
(n = 102), and non-recent (n = 67) HIV infection (see text). For each column, the median (closed square), interquartile range (IQR, box), lower inner
fence (first quartile [Q1] – [1.5 X IQR]) and upper inner fence (third quartile [Q3] + [1.5 X IQR], whiskers), outliers (greater than [Q3] + [1.5 x IQR], open
circle) and extremes (greater than [Q3] + [3 x IQR], asterisk) are shown.
doi:10.1371/journal.pone.0027211.g002
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for all regions except GAG2. This indicates that the HRM
diversity assay can detect a low level of HIV diversity very early in
HIV infection. In adults with acute HIV infection, the highest
median HRM score was obtained for the ENV2 region, which
contains IDR cluster I of gp41. HRM scores for all regions except
for ENV2 were significantly higher in seropositive adults with
recent HIV infection than in adults with acute HIV infection.
In all six regions analyzed, we found significantly higher levels of
HIV diversity in adults who were infected for at least two years
(non-recent group) than in adults near the time of HIV
seroconversion (recent group). An important finding of this study
was that viruses from individuals with non-recent infection often
exhibited low diversity in at least one of the regions analyzed; in
each region, there was some overlap in the HRM scores from
adults with recent and non-recent infection. A similar finding was
reported in a study that used a heteroduplex mobility assay to
compare HIV diversity in the V3-V5 region of HIV env in adults
with likely recent vs. likely non-recent infection (classified using a
detuned enzyme immunoassay strategy) [36]. These findings and
ours indicate that diversity-based measures (obtained using the
HRM diversity assay or another method for viral diversity analysis)
are not likely to be useful for HIV incidence analysis if they rely on
analysis of a single genomic region. Our study extends the previous
report [36] by comparing diversity in multiple genomic regions
and by using sample sets from individuals with known recent and
known non-recent infection. This expanded analysis revealed that
individuals with non-recent HIV infection rarely had low diversity
in all regions that we examined. Furthermore, multivariate logistic
regression showed that higher HRM scores in three regions
(GAG2, ENV1, and ENV3) were independently associated with
non-recent HIV infection. Independent diversification in different
regions of the HIV genome is likely to reflect several factors,
including: (1) different selective forces act on different HIV gene
products, inducing diversification of different genomic regions,
and (2) the very high frequency of genetic recombination of HIV
lowers genetic linkage of different subgenomic regions. Our
findings suggest that HIV diversity may be a useful biomarker for
HIV incidence determination, provided that multiple HIV
genomic regions are analyzed. The HRM diversity assay is
simpler and less expensive than many other laboratory approaches
used to measure HIV diversity, and it is particularly well-suited to
multi-region analysis. The HRM diversity assay can be used to
measure diversity in any RNA or DNA sample, including HIV
RNA and proviral DNA. For HIV incidence applications, it makes
most sense to analyze the actively replicating pool (e.g., plasma
HIV RNA) rather than proviral DNA, which is likely to include
archived sequences from viruses that were circulating earlier in
infection.
Table 2. Comparison of HRM scores from adults with recent vs. non-recent HIV infection*.
Region analyzeda Univariate model Multivariate model
Odds ratio (95% CI) P value Odds ratiob (95% CI) P value
GAG1 0.20 (0.10–0.34) ,0.001 0.60 (0.29–1.18) 0.15
GAG2 0.27 (0.17–0.40) ,0.001 0.58 (0.32–0.95) 0.04
POL 0.10 (0.05–0.20) ,0.001 0.60 (0.25–1.54) 0.33
ENV1 0.03 (0.006–0.08) ,0.001 0.17 (0.04–0.52) 0.004
ENV2 0.72 (0.54–0.95) 0.02 0.92 (0.56–1.51) 0.73
ENV3 0.07 (0.03–0.15) ,0.001 0.20 (0.07–0.46) ,0.001
*Abbreviations: HRM: high resolution melting. CI: confidence intervals. Recent samples were collected a median of 189 days after a negative HIV test (range: 14–540
days); non-recent samples were from individuals infected .2 years (see Methods). Results from adults with acute HIV infection were not included in this analysis.
Statistically significant values are shown in bold text.
aSee Figure 1.
bBased on multivariate logistic regression adjusting for all regions simultaneously.
doi:10.1371/journal.pone.0027211.t002
Figure 3. Relationship between HRM scores for the ENV1, ENV2, and GAG2 regions. Scatter plots are shown for HRM scores for adults with
acute, recent, and non-recent infection: (A) ENV1 vs. GAG2, (B) ENV3 vs. GAG2, and (C) ENV1 vs. ENV3.
doi:10.1371/journal.pone.0027211.g003
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Advanced HIV disease is associated with misclassification of
individuals with non-recent infection as recently infected using
serologic incidence assays [3]. Our results indicate that this is not
likely to confound the use of the HRM diversity assay for HIV
incidence testing. In this study, almost half (48%) of the samples in
the non-recent group were from individuals with CD4 cell counts
,50 cells/mm3. In the non-recent group, HRM scores were not
significantly different among adults with CD4 cell counts above vs.
below 50 cells/mm3, and all of the unusually high HRM scores in
this group (outlier and extreme values) were from adults with CD4
cell counts ,50 cells/mm3. These data show that advanced HIV
disease is not associated with misclassification using the HRM
diversity assay, and suggest that the HRM diversity assay may be
useful for identifying samples from adults with advanced HIV
disease who were misclassified as recently infected using serologic
incidence assays.
Viral suppression is also associated with misclassification of
individuals with non-recent infection as recently infected using
serologic incidence assays [3]. In this study, samples from adults on
ART had detectable HIV RNA (to permit amplification of HIV
RNA for analysis); it is not known whether those individuals were
non-adherent to their treatment regimens or were failing ART.
Because the HRM diversity assay uses different primer pairs for
amplification of various regions of the HIV genome, and because
the primers are designed to bind to relatively conserved sequences,
sequence differences in HIV samples are not likely to impair
binding of all of the relevant primer pairs. Therefore, amplification
failure for all primer pairs is likely to indicate low viral load. We do
not feel that it is necessary to screen samples for viral load prior to
testing with the HRM diversity assay. If desired, a viral load assay
could be used to confirm viral suppression in samples with multi-
region amplification failure. We recognize that recently-infected
individuals who have very low viral loads could be misclassified as
non-recent if virologic suppression is used as a biomarker for non-
recent infection. However, because infected individuals are not
likely to have natural or ART-induced viral suppression early in
infection, this type of misclassification should be infrequent and
should have very little impact on HIV incidence estimates.
For samples that do amplify, we recognize that there is a
potential to underestimate diversity when fewer copies of HIV
RNA are used in the analysis. However, in a previous study [23],
we demonstrated that results from the HRM diversity assay were
not significantly affected by differences in sample volume (0.1 vs.
0.5 ml), HIV viral load (range: 2,000 to 50,000 copies/ml), or the
number of HIV RNA copies used to prepare DNA templates for
amplification (range: 100 to 5,000 copies of HIV RNA). Those
results support the use of the HRM diversity assay for analysis of
clinical samples with variable viral loads.
The HRM diversity assay provides data that is likely to be
independent of data from serologic incidence tests. Therefore, use
of the HRM diversity assay in combination with serologic testing is
likely to improve the precision of multi-assay algorithms for HIV
incidence, lowering misclassification rates. Figure 5A shows an
example of an existing multi-assay algorithm that combines four
Table 3. Comparison of HRM scores from recently infected
individuals from the HIVNET 001 cohort and the EXPLORE
cohort*.
Region
analyzeda HRM Score
b
P valuec
HIVNET 001 (n =14) EXPLORE (n =102)
GAG1 4.8 (4.7, 4.9) 4.8 (4.7, 4.9) 0.95
GAG2 4.4 (4.1, 4.7) 4.2 (4.0, 4.5) 0.13
POL 4.3 (4.1, 4.4) 4.3 (4.3, 4.6) 0.24
ENV1 4.4 (4.3, 4.4) 4.5 (4.4, 4.7) 0.02
ENV2 4.6 (4.4, 4.8) 5.1 (4.6, 6.2) 0.01
ENV3 4.7 (4.4, 5.6) 4.7 (4.5, 4.9) 0.55
*Abbreviations: HRM: high resolution melting. CI: confidence intervals.
aSee Figure 1.
bHRM scores were obtained for samples collected from adults with recent HIV
infection. Samples from the HIVNET 001 cohort were obtained from women
and from men who likely acquired HIV through intravenous drug use. Samples
from the EXPLORE cohort were obtained from men who likely acquired HIV
infection through sexual exposure with other men. The median number of
days between collection of the sample used for testing and the individual’s last
negative HIV tests was 165 days (range: 49–216) for the HIVNET 001 cohort and
189 days (range: 14–540) for the EXPLORE cohort. Median HRM scores and the
first and third quartile HRM scores (in parentheses) are shown.
cWilcoxon Rank sum test.
doi:10.1371/journal.pone.0027211.t003
Figure 4. HRM diversity scores for GAG2, ENV1 and ENV3 plotted in 3 dimensions. High HRM scores for these regions were determined to
be independently associated with non-recent infection. The use of data from multiple regions in tandem demonstrates that HRM scores are generally
compact in acute infection (A) with a slight increase in the distribution of data in recent infection (B), and wide dispersion of the data in non-recent
infection (C).
doi:10.1371/journal.pone.0027211.g004
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assays for HIV incidence determination: a BED screening assay
and an avidity screening assay (using a high cut-off for recent HIV
infection for both assays), CD4 cell count, and viral load
[23,37,38]. While CD4 cell count is a useful biomarker for
reducing misclassification, inclusion of CD4 cell count data in
incidence algorithms presents certain logistical challenges. First,
because CD4 cell counts must be obtained in real-time (before
other HIV incidence testing has been performed), CD4 cell count
testing must be performed for all HIV-infected individuals
evaluated, rather than the smaller subset who appear to be
recently infected based on serologic testing. Second, many
valuable sample sets from clinical trials and surveillance studies
include only stored serum or plasma. Unless CD4 cell counts were
obtained at the time of sample collection, it is not possible to assess
incidence in those sample sets using an algorithm that includes
CD4 cell count data.
We are exploring whether inclusion of the HRM diversity assay
as part of a multi-assay algorithm will eliminate the need for CD4
cell count data, allowing all of the testing to be performed using a
single plasma or serum sample. Figure 5B shows a possible
alternative multi-assay algorithm that incorporates the HRM
diversity assay. To reduce the cost and effort needed for analysis, it
would be most effective to screen samples for recent infection using
serologic HIV incidence assays (e.g., BED and avidity screens).
The subset of samples that are classified as ‘‘recent’’ based on
serologic testing could then be tested using the HRM diversity
assay to improve the precision of HIV incidence estimates. With
this analytic plan, the number of samples that would require HRM
diversity analysis would be relatively small. Therefore, the cost of
the HRM diversity assay would not greatly impact the overall cost
of the incidence assessment. Our preliminary data suggest that
HIV from recently-infected individuals usually lacks diversity
across the HIV genome, while HIV from individuals with non-
recent infection is genetically diverse in one or more genomic
regions. Studies are underway to identify genomic regions and
assay cutoffs in each region that optimally discriminate between
recent and non-recent infection. Once those parameters are set, it
might be possible to use a simple approach in which samples are
characterized as non-recent if they have a high HRM score in at
least one of several regions tested.
In summary, this study provides proof of principle that HIV
diversity can be used as a biomarker to distinguish between adults
with recent vs. non-recent HIV infection. Further studies are
needed to evaluate the performance of multi-assay algorithms for
Figure 5. Use of the HRM diversity assay as part of a multi-assay algorithm for HIV incidence determination. Panel A shows one
example of a multi-assay algorithm developed for HIV incidence determination. In this algorithm, samples from HIV-infected individuals are first
tested using the BED-CEIA assay, using a high assay cutoff to indicate non-recent HIV infection (BED screen). Samples that are below the BED screen
cutoff (BED recent samples) are then tested using a second serologic assay, such as one based on antibody avidity (avidity screen). Samples that are
below the cutoff for the second serologic assay are considered to be ‘‘serologic recent’’ samples. Samples with low CD4 cell count test results are then
excluded as non-recent (note that CD4 cell count test results are usually obtained for all HIV-infected individuals at the time of sample collection).
Finally, samples that are not excluded based on CD4 cell count are tested using a viral load assay, and samples with low viral loads are excluded as
non-recent. The remaining samples are characterized as recent for the purpose of estimating HIV incidence. Panel B shows an alternative multi-assay
algorithm that incorporates the HRM diversity assay. In this algorithm, samples that are characterized as serologic recent based on two assays (BED
screen and an avidity screen) are tested with a multi-region HRM diversity assay. Samples that have a high HRM score in at least one of the regions
tested are excluded as non-recent. Samples that fail to amplify in all regions tested are also excluded as non-recent, based on the assumption that
they have low viral loads; this could be confirmed with a viral load assay. Samples that have low HRM scores in all regions tested are characterized as
recent for the purpose of estimating HIV incidence.
doi:10.1371/journal.pone.0027211.g005
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HIV incidence determination that include the HRM diversity
assay.
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